• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Doebele Robert

    2/3/25 6:29:34 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BOLD alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Doebele Robert

    (Last) (First) (Middle)
    C/O BOUNDLESS BIO, INC.
    10955 ALEXANDRIA WAY, SUITE 100

    (Street)
    SAN DIEGO CA 92121

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    02/03/2025
    3. Issuer Name and Ticker or Trading Symbol
    Boundless Bio, Inc. [ BOLD ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Medical Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24 - Power of Attorney.
    No securities are beneficially owned.
    /s/ Jessica Oien, Attorney- in-Fact for Robert Doebele 02/03/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BOLD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BOLD

    DatePrice TargetRatingAnalyst
    6/2/2025$5.00Buy
    H.C. Wainwright
    5/28/2025$3.00Outperform → Market Perform
    Leerink Partners
    12/13/2024Buy → Neutral
    Guggenheim
    More analyst ratings

    $BOLD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights

    BBI-355 and BBI-825 combination arm of the POTENTIATE trial is now open for enrollment BBI-940 is on track for submission of an investigational new drug application in the first half of 2026 $127 million in cash supports operations into the first half of 2028, throughexpected proof-of-concept clinical readouts for both programs SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) --  Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fisc

    8/5/25 7:00:00 AM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board

    HOUSTON, July 31, 2025 /PRNewswire/ -- The Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of Rice University's health and medical technology discoveries into cures, announced today the appointment of Carolyn Ng to its external advisory board. A current business unit partner at TPG Life Sciences Innovations, Ng brings expertise in biotech and company building with a track record of guiding early to midstage companies across a wide range of therapeutic areas. "Carolyn's deep understanding of translational science, combined with her passion for fostering high-impact ventures, makes her an ideal addition to the board," said Omid Veiseh, professor of b

    7/31/25 7:00:00 AM ET
    $BCAX
    $BCYC
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

    SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that   Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference. The fireside chat session is scheduled for Monday, June 9, in Miami, FL, at 9:20 a.m. ET. A live and archived webcast of the session will be accessible under "Events & Presentations" in the Investors section of Boundless Bio's website. About Boundless

    6/5/25 4:58:28 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Brennan Christine

    4 - Boundless Bio, Inc. (0001782303) (Issuer)

    6/23/25 5:21:20 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Christensen James

    4 - Boundless Bio, Inc. (0001782303) (Issuer)

    6/23/25 5:16:53 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Lew Jennifer

    4 - Boundless Bio, Inc. (0001782303) (Issuer)

    6/23/25 5:15:17 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLD
    Financials

    Live finance-specific insights

    View All

    Boundless Bio Announces Portfolio Prioritization and Runway Extension

    Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first half of 2028, through expected proof-of-concept clinical readouts for each program Conference call and webcast to be held Tuesday, May 27 at 8:00 am ET SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today provided business updates focused on optimizing the Company's portfolio for p

    5/23/25 4:01:00 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Boundless Bio Inc.

    SC 13D - Boundless Bio, Inc. (0001782303) (Subject)

    10/29/24 6:32:08 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Boundless Bio with a new price target

    H.C. Wainwright initiated coverage of Boundless Bio with a rating of Buy and set a new price target of $5.00

    6/2/25 8:50:41 AM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boundless Bio downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Boundless Bio from Outperform to Market Perform and set a new price target of $3.00

    5/28/25 8:09:07 AM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boundless Bio downgraded by Guggenheim

    Guggenheim downgraded Boundless Bio from Buy to Neutral

    12/13/24 7:26:11 AM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLD
    Leadership Updates

    Live Leadership Updates

    View All

    Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board

    HOUSTON, July 31, 2025 /PRNewswire/ -- The Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of Rice University's health and medical technology discoveries into cures, announced today the appointment of Carolyn Ng to its external advisory board. A current business unit partner at TPG Life Sciences Innovations, Ng brings expertise in biotech and company building with a track record of guiding early to midstage companies across a wide range of therapeutic areas. "Carolyn's deep understanding of translational science, combined with her passion for fostering high-impact ventures, makes her an ideal addition to the board," said Omid Veiseh, professor of b

    7/31/25 7:00:00 AM ET
    $BCAX
    $BCYC
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer

    SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Robert ("Bob") Doebele, M.D., Ph.D., has been appointed as Chief Medical Officer. "We are excited to have Bob join Boundless at this pivotal time as we continue to advance the BBI-355 Phase 1/2 POTENTIATE trial and approach the selection of a development candidate for our Kinesin program," said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. "Bob has been a driving force behind precisio

    2/3/25 10:00:00 AM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLD
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Boundless Bio Inc.

    SCHEDULE 13G/A - Boundless Bio, Inc. (0001782303) (Subject)

    8/14/25 5:57:29 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Boundless Bio Inc.

    10-Q - Boundless Bio, Inc. (0001782303) (Filer)

    8/5/25 7:10:20 AM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boundless Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Boundless Bio, Inc. (0001782303) (Filer)

    8/5/25 7:05:28 AM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care